(Reuters) - European health regulators on Friday conditionally approved Amgen Inc’s rare blood cancer drug, Blincyto, which is one of the world’s most expensive cancer treatments.
The U.S. Food and Drug Administration in December approved Blincyto for acute lymphoblastic leukemia (ALL), which has few treatment options once a patient has relapsed.
Blincyto is a so-called bispecific antibody, an emerging class of drugs that could prove more potent than conventional antibodies – the mainstay treatment for many forms of cancers.
An estimated 6,250 Americans, mostly children, will be diagnosed with ALL this year and 1,450 of them will succumb to the disease, according to the American Cancer Society.
The European Medicines Agency conditionally approves a drug when it is meant for a severely debilitating disease with few or no treatment options, and when the benefits of its immediate availability outweigh the risks.
The conditional approval is granted despite the lack of complete trial data and is renewed annually until the EMA is satisfied with the complete data to fully approve the drug.
Amgen, the world’s largest biotechnology company, expects final European approval for Blincyto in the coming months.
The drug, which it got through the acquisition of biotechnology company Micromet in 2012, costs about $178,000 for two courses of treatment.
Pharmaceutical companies have recently come under fire over high prices for specialty drugs and U.S. Democratic presidential candidate Hillary Clinton unveiled a plan on Wednesday to address “price gouging”.
European regulators on Friday also backed Amgen’s multiple myeloma drug, Kyprolis, for its use in combination with two other drugs in previously-treated patients.
The blood cancer drug is being used as a monotherapy in the United States since 2012, and in July this year was cleared by the FDA to be used in combination with lenalidomide and dexamethasone.
Thousand Oaks, California-based Amgen’s stock was up nearly 2 percent at $146.24 in early trading on Friday.
Reporting by Natalie Grover and Abhiram Nandakumar in Bengaluru; Editing by Savio D'Souza